Abstract
Telomeres are protective structures located at the end of eukaryotic chromosomes which are shortened after each cell division, leading to senescence. Telomerase activity prevents telomere shortening by reverse transcription catalyzed by the subunit called TERT (telomerase reverse transcriptase). TERT expression has shown interesting cellular properties, which may be appealing for tissue engineering, such as the enhancement of cell proliferation and differentiation abilities in vitro. Despite some evidence for playing these roles in VEGF (vascular endothelial growth factor)-mediated angiogenesis, it is still unclear whether TERT can contribute to this essential event to generate functional organs. This review suggests a hypothesis that TERT and VEGF potentially regulates the transcriptional expression of each other, which would give new perspectives in the roles of telomerase in regulating several cellular processes, and also contributing for a better comprehension of the molecular mechanisms underlying VEGF signaling (both paracrine and autocrine). In general, based on the literature revised, it is possible to conclude that TERT is a potential VEGF enhancer; however, it is necessary to elaborate methodological approaches to explore this potential and to assess the potential benefits on tissue engineering approaches.
References
Martinez, P., & Blasco, M. A. (2011). Telomeric and extra-telomeric roles for telomerase and the telomere-binding proteins. Nature Reviews Cancer, 11, 161–176.
de Lange, L. T. (2005). Shelterin: the protein complex that shapes and safeguards human telomeres. Genes Development, 19, 2100–2110.
Blackburn, E. H. (2005). Telomeres and telomerase: their mechanisms of action and the effects of altering their functions. FEBS Letters, 579, 859–862.
Pampalona, J., Soler, D., Genesca, A., & Tusell, L. (2010). Telomere dysfunction and chromosome structure modulate the contribution of individual chromosomes in abnormal nuclear morphologies. Mutation Research, 683, 16–22.
Pampalona, J., Soler, D., Genesca, A., & Tusell, L. (2010). Whole chromosome loss is promoted by telomere dysfunction in primary cells. Genes, Chromosomes and Cancer, 49, 368–378.
Hornsby, P. J. (2010). Cellular aging and cancer. Critical Reviews Oncology/Hematology, 79, 189–195.
Deng, Y., Chan, S. S., & Chang, S. (2008). Telomere dysfunction and tumour suppression: the senescence connection. Nature Reviews Cancer, 8, 450–458.
Hayflick, L., & Moorhead, P. S. (1961). The serial cultivation of human diploid cell strains. Experimental Cell Research, 25, 585–621.
Olovnikov, A. M. (1973). A theory of marginotomy. The incomplete copying of template margin in enzymic synthesis of polynucleotides and biological significance of the phenomenon. Journal of Theoretical Biology, 41, 181–190.
Good, P. I. (1977). Astochastic model for in vitro ageing II. A theory of marginotomy. Journal of Theoretical Biology, 64, 261–275.
Harley, C. B., Futcher, A. B., & Greider, C. W. (1990). Telomeres shorten during ageing of human fibroblasts. Nature, 345, 458–460.
Allsopp, R. C., Vaziri, H., Patterson, C., Goldstein, S., Younglai, E. V., Futcher, A. B., et al. (1992). Telomere length predicts replicative capacity of human fibroblasts. Proceedings of the National Academy of Sciences of the United States of America, 89, 10114–10118.
Wright, W. E., & Shay, J. W. (1992). The two-stage mechanism controlling cellular senescence and immortalization. Experimental Gerontology, 27, 383–389.
Maser, R. S., & Depinho, R. A. (2002). Connecting chromosomes, crisis, and cancer. Science, 297, 565–569.
Greider, C. W., & Blackburn, E. H. (1987). The telomere terminal transferase of Tetrahymena is a ribonucleoprotein enzyme with two kinds of primer specificity. Cell, 51, 887–898.
Cohen, S. B., Graham, M. E., Lovrecz, G. O., Bache, N., Robinson, P. J., & Reddel, R. R. (2007). Protein composition of catalytically active human telomerase from immortal cells. Science, 315, 1850–1853.
Wright, W. E., Piatyszek, M. A., Rainey, W. E., Byrd, W., & Shay, J. W. (1996). Telomerase activity in human germline and embryonic tissues and cells. Developmental Genetics, 18, 173–179.
Liu, L., Bailey, S. M., Okuka, M., Munoz, P., Li, C., Zhou, L., et al. (2007). Telomere lengthening early in development. Nature Cell Biology, 9, 1436–1441.
Shay, J. W., & Bacchetti, S. (1997). A survey of telomerase activity in human cancer. European Journal of Cancer, 33, 787–791.
Belair, C. D., Yeager, T. R., Lopez, P. M., & Reznikoff, C. A. (1997). Telomerase activity: a biomarker of cell proliferation, not malignant transformation. Proceedings of the National Academy of Sciences of the United States of America, 94, 13677–13682.
Flores, I., Benetti, R., & Blasco, M. A. (2006). Telomerase regulation and stem cell behaviour. Current Opinion in Cell Biology, 18, 254–260.
Shukla, S., Acharya, S., Rajput, D., Vagha, S., & Grover, S. (2010). Telomere–the twilight to immortality. Journal of the Association of Physicians of India, 58, 553–560.
Flores, I., Cayuela, M. L., & Blasco, M. A. (2005). Effects of telomerase and telomere length on epidermal stem cell behavior. Science, 309, 1253–1256.
Rossi, D. J., Bryder, D., Seita, J., Nussenzweig, A., Hoeijmakers, J., & Weissman, I. L. (2007). Deficiencies in DNA damage repair limit the function of haematopoietic stem cells with age. Nature, 447, 725–729.
Wong, K. K., Maser, R. S., Bachoo, R. M., Menon, J., Carrasco, D. R., Gu, Y., et al. (2003). Telomere dysfunction and Atm deficiency compromises organ homeostasis and accelerates ageing. Nature, 421, 643–648.
Ferron, S., Mira, H., Franco, S., Cano-Jaimez, M., Bellmunt, E., Ramirez, C., et al. (2004). Telomere shortening and chromosomal instability abrogates proliferation of adult but not embryonic neural stem cells. Development, 131, 4059–4070.
Ferron, S. R., Marques-Torrejon, M. A., Mira, H., Flores, I., Taylor, K., Blasco, M. A., et al. (2009). Telomere shortening in neural stem cells disrupts neuronal differentiation and neuritogenesis. Journal of Neuroscience, 29, 14394–14407.
Weinrich, S. L., Pruzan, R., Ma, L., Ouellette, M., Tesmer, V. M., Holt, S. E., et al. (1997). Reconstitution of human telomerase with the template RNA component hTR and the catalytic protein subunit hTRT. Nature Genetics, 17, 498–502.
Bodnar, A. G., Ouellette, M., Frolkis, M., Holt, S. E., Chiu, C. P., Morin, G. B., et al. (1998). Extension of life-span by introduction of telomerase into normal human cells. Science, 279, 349–352.
Laschke, M. W., Harder, Y., Amon, M., Martin, I., Farhadi, J., Ring, A., et al. (2006). Angiogenesis in tissue engineering: breathing life into constructed tissue substitutes. Tissue Engineering, 12, 2093–2104.
Demarco, F. F., Conde, M. C., Cavalcanti, B. N., Casagrande, L., Sakai, V. T., & Nor, J. E. (2011). Dental pulp tissue engineering. Brazilian Dental Journal, 22, 3–13.
Nedel, F., Andre, D. A., de Oliveira, I. O., Cordeiro, M. M., Casagrande, L., Tarquinio, S. B., et al. (2009). Stem cells: therapeutic potential in dentistry. Journal of Contemporary Dental Practice, 10, 90–96.
Sakai, V. T., Cordeiro, M. M., Dong, Z., Zhang, Z., Zeitlin, B. D., & Nor, J. E. (2011). Tooth slice/scaffold model of dental pulp tissue engineering. Advances in Dental Research, 23, 325–332.
Hegen, A., Blois, A., Tiron, C. E., Hellesoy, M., Micklem, D. R., Nor, J. E., et al. (2011). Efficient in vivo vascularization of tissue-engineering scaffolds. Journal of Tissue Engineering and Regenerative Medicine, 5, e52–e62.
Senger, D. R., Galli, S. J., Dvorak, A. M., Perruzzi, C. A., Harvey, V. S., & Dvorak, H. F. (1983). Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science, 219, 983–985.
Koch, S., Tugues, S., Li, X., Gualandi, L., & Claesson-Welsh, L. (2011). Signal transduction by vascular endothelial growth factor receptors. Biochemical Journal, 437, 169–183.
Zeitlin, B. D., Ellis, L. M., & Nor, J. E. (2009). Inhibition of vascular endothelial growth factor receptor-1/Wnt/{beta}-catenin crosstalk leads to tumor cell death. Clinical Cancer Research, 15, 7453–7455.
Giordano, R. J., Cardo-Vila, M., Salameh, A., Anobom, C. D., Zeitlin, B. D., Hawke, D. H., et al. (2010). From combinatorial peptide selection to drug prototype (I): targeting the vascular endothelial growth factor receptor pathway. Proceedings of the National Academy of Sciences of the United States of America, 107, 5112–5117.
Armstrong, L., Saretzki, G., Peters, H., Wappler, I., Evans, J., Hole, N., et al. (2005). Overexpression of telomerase confers growth advantage, stress resistance, and enhanced differentiation of ESCs toward the hematopoietic lineage. Stem Cells, 23, 516–529.
Indran, I. R., Hande, M. P., & Pervaiz, S. (2011). hTERT overexpression alleviates intracellular ROS production, improves mitochondrial function, and inhibits ROS-mediated apoptosis in cancer cells. Cancer Research, 71, 266–276.
Yang, C., Przyborski, S., Cooke, M. J., Zhang, X., Stewart, R., Anyfantis, G., et al. (2008). A key role for telomerase reverse transcriptase unit in modulating human embryonic stem cell proliferation, cell cycle dynamics, and in vitro differentiation. Stem Cells, 26, 850–863.
Sirma, H., Kumar, M., Meena, J. K., Witt, B., Weise, J. M., Lechel, A., et al. (2011). The promoter of human telomerase reverse transcriptase is activated during liver regeneration and hepatocyte proliferation. Gastroenterology, 141(326–37), 337.
Liang, X. J., Chen, X. J., Yang, D. H., Huang, S. M., Sun, G. D., & Chen, Y. P. (2011). Differentiation of human umbilical cord mesenchymal stem cells into hepatocyte-like cells by hTERT gene transfection in vitro. Cell Biology International, 36, 215–221.
He, X. Y., Zheng, Y. M., Lan, J., Wu, Y. H., Yan, J., He, X. N., et al. (2011). Recombinant adenovirus-mediated human telomerase reverse transcriptase gene can stimulate cell proliferation and maintain primitive characteristics in bovine mammary gland epithelial cells. Development, Growth & Differentiation, 53, 312–322.
Tsai, C. C., Chen, C. L., Liu, H. C., Lee, Y. T., Wang, H. W., Hou, L. T., et al. (2010). Overexpression of hTERT increases stem-like properties and decreases spontaneous differentiation in human mesenchymal stem cell lines. Journal of Biomedical Science, 17, 64.
Mi, H. W., Lee, M. C., Fu, E., Chow, L. P., & Lin, C. P. (2011). Highly efficient multipotent differentiation of human periodontal ligament fibroblasts induced by combined BMP4 and hTERT gene transfer. Gene Therapy, 18, 452–461.
Asumda, F. Z., & Chase, P. B. (2011). Age-related changes in rat bone-marrow mesenchymal stem cell plasticity. BMC Cell Biology, 12, 44.
Tang, J., Wang, Z., Li, X., Li, J., & Shi, H. (2008). Human telomerase reverse transcriptase expression correlates with vascular endothelial growth factor-promoted tumor cell proliferation in prostate cancer. Artificial Cells, Blood Substitutes and Biotechnology, 36, 83–93.
Kirkpatrick, K. L., Newbold, R. F., & Mokbel, K. (2004). The mRNA expression of hTERT in human breast carcinomas correlates with VEGF expression. Journal of Carcinogenesis, 3, 1.
Bermudez, Y., Yang, H., Saunders, B. O., Cheng, J. Q., Nicosia, S. V., & Kruk, P. A. (2007). VEGF- and LPA-induced telomerase in human ovarian cancer cells is Sp1-dependent. Gynecologic Oncolcology, 106, 526–537.
Zhou, L., Zheng, D., Wang, M., & Cong, Y. S. (2009). Telomerase reverse transcriptase activates the expression of vascular endothelial growth factor independent of telomerase activity. Biochemical and Biophysical Research Communications, 386, 739–743.
Shkreli, M., Sarin, K. Y., Pech, M. F., Papeta, N., Chang, W., Brockman, S. A., et al. (2012). Reversible cell-cycle entry in adult kidney podocytes through regulated control of telomerase and Wnt signaling. Nature Medicine, 18, 111–119.
Strong, M. A., Vidal-Cardenas, S. L., Karim, B., Yu, H., Guo, N., & Greider, C. W. (2011). Phenotypes in mTERT/ and mTERT/ mice are due to short telomeres, not telomere-independent functions of telomerase reverse transcriptase. Molecular and Cell Biology, 31, 2369–2379.
Donnini, S., Solito, R., Cetti, E., Corti, F., Giachetti, A., Carra, S., et al. (2010). Abeta peptides accelerate the senescence of endothelial cells in vitro and in vivo, impairing angiogenesis. The Journal of the Federation of American Societies for Experimental Biology, 24, 2385–2395.
Minamino, T., & Komuro, I. (2008). Vascular aging: insights from studies on cellular senescence, stem cell aging, and progeroid syndromes. Nature Reviews Cardiology, 5, 637–648.
Zaccagnini, G., Gaetano, C., Della, P. L., Nanni, S., Grasselli, A., Mangoni, A., et al. (2005). Telomerase mediates vascular endothelial growth factor-dependent responsiveness in a rat model of hind limb ischemia. Journal of Biological Chemistry, 280, 14790–14798.
Baumer, Y., Funk, D., & Schlosshauer, B. (2010). Does telomerase reverse transcriptase induce functional de-differentiation of human endothelial cells? Cellular and Molecular Life Sciences, 67, 2451–2465.
Shi, A. W., Gu, N., Liu, X. M., Wang, X., & Peng, Y. Z. (2011). Ginsenoside rg1 enhances endothelial progenitor cell angiogenic potency and prevents senescence in vitro. Journal of International Medical Research, 39, 1306–1318.
Chang, E., & Harley, C. B. (1995). Telomere length and replicative aging in human vascular tissues. Proceedings of the National Academy of Sciences of the United States of America, 92, 11190–11194.
Fadini, G. P., & Avogaro, A. (2010). Cell-based methods for ex vivo evaluation of human endothelial biology. Cardiovascular Research, 87, 12–21.
Yoder, M. C. (2010). Is endothelium the origin of endothelial progenitor cells? Arteriosclerosis, Thrombosis, and Vascular Biology, 30, 1094–1103.
Lee, S., Chen, T. T., Barber, C. L., Jordan, M. C., Murdock, J., Desai, S., et al. (2007). Autocrine VEGF signaling is required for vascular homeostasis. Cell, 130, 691–703.
Harley, C. B., Liu, W., Blasco, M., Vera, E., Andrews, W. H., Briggs, L. A., et al. (2011). A natural product telomerase activator as part of a health maintenance program. Rejuvenation Research, 14, 45–56.
de Jesus, B.B., Schneeberger, K., Vera, E., Tejera, A., Harley, C.B., & Blasco, M.A. (2011). The telomerase activator TA-65 elongates short telomeres and increases health span of adult/old mice without increasing cancer incidence. Aging Cell
Hanahan, D., & Weinberg, R. A. (2011). Hallmarks of cancer: the next generation. Cell, 144, 646–674.
Xie, M., Chen, Q., He, S., Li, B., & Hu, C. (2011). Silencing of the human TERT gene by RNAi inhibits A549 lung adenocarcinoma cell growth in vitro and in vivo. Oncology Reports, 26, 1019–1027.
Kotsakis, A., Vetsika, E. K., Christou, S., Hatzidaki, D., Vardakis, N., Aggouraki, D., et al. (2012). Clinical outcome of patients with various advanced cancer types vaccinated with an optimized cryptic human telomerase reverse transcriptase (TERT) peptide: results of an expanded phase II study. Annals of Oncology, 23, 442–449.
Feldser, D. M., Hackett, J. A., & Greider, C. W. (2003). Telomere dysfunction and the initiation of genome instability. Nature Reviews Cancer, 3, 623–627.
Author information
Authors and Affiliations
Corresponding authors
Rights and permissions
About this article
Cite this article
Hartwig, F.P., Nedel, F., Collares, T.V. et al. Telomeres and Tissue Engineering: The Potential Roles of TERT in VEGF-mediated Angiogenesis. Stem Cell Rev and Rep 8, 1275–1281 (2012). https://doi.org/10.1007/s12015-012-9414-3
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12015-012-9414-3